{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:06:55Z","timestamp":1776668815117,"version":"3.51.2"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>B-cell depletion with anti-CD20 monoclonal antibody (mAb) represents a novel and highly effective treatment for patients with multiple sclerosis. Although all approved anti-CD-20 mAbs for multiple sclerosis (MS) treatment, ocrelizumab, ofatumumab, and ublituximab, target the same molecule on the B-cell surface, some differences in their molecular structure translate into important distinctions in their mechanisms of B-cell depletion. Differences between an antibody-dependent cell-mediated cytotoxicity (ADCC) versus a complement-dependent cytotoxicity (CDC) in anti-CD20 mAbs mechanism of action correspond to deeper B-cell depletion as well as better tolerability. Glycoengineering of the Fc portion of ublituximab with reduced fucosylation enhances affinity to Fc gamma receptor IIIa (Fc\u03b3RIIIa) on natural killer (NK) cells. This molecular modification of ublituximab exhibits significantly higher ADCC activity in relation to CDC in B-cell depletion mechanisms. In addition, glycoengineering of ublituximab reduces the importance of the Fc\u03b3RIIIa 158V\/F polymorphism, which influences the effectiveness of B-cell depletion. In the ULTIMATE I and II studies, ublituximab showed a significant reduction in annual relapse rate versus teriflunomide in relapsing MS patients and strikingly reduced active and new\/enlarging MRI lesions. Ublituximab also showed efficacy on the disease progression and increased disability improvement in the extended 5-year observation study. The advantage of ublituximab also correlates with good tolerability and reduced infusion-related reactions. Ublituximab infusion, 1\u2009h, is significantly shorter in comparison to other intravenous (IV) preparations of anti-CD20 mAbs. Thus, ublituximab provides better convenience to MS patients as well as saves the time of healthcare providers.<\/jats:p>","DOI":"10.1177\/17562864261434868","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:12:10Z","timestamp":1774894330000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A new glycoengineered form of anti-CD20 monoclonal antibody in treatment of multiple sclerosis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-7218","authenticated-orcid":false,"given":"Krzysztof","family":"Selmaj","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurosurgery, University of Warmia and Mazury, 30 Warszawska Street, Olsztyn 10-082, Poland Center of Neurology, Lodz, Poland"},{"name":"Center of Neurology, 12 Tylna Street, 90-324 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Neurology at the University Hospitals of the Ruhr-University Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Selmaj","sequence":"additional","affiliation":[{"name":"Center of Neurology, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin P.","family":"Mycko","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University of Warmia and Mazury, Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10744-x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21363"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.06.029"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27012"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2268842"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795"},{"key":"e_1_3_4_13_2","first-page":"7","article-title":"Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC","volume":"3","author":"Natsume A","year":"2009","unstructured":"Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3: 7\u201316.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-011-9377-2"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00077-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102787"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq027"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315174"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1109"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1276"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104343"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51911"},{"key":"e_1_3_4_27_2","volume-title":"Presented at the Joint ECTRIMS-ACTRIMS Meeting: MSMilan 2023","author":"Abbadessa G","unstructured":"Abbadessa G, Miele G, Benedetti R, et al. Influence of FCGR3A-V158F polymorphism on the therapeutic response to ocrelizumab in patients with relapsing multiple sclerosis. In: Presented at the Joint ECTRIMS-ACTRIMS Meeting: MSMilan 2023; 11\u201313 October 2023; Milan, Italy."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02011-w"},{"key":"e_1_3_4_29_2","unstructured":"Hartung H-P Steinman L Fox EJ et al. Ublituximab efficacy outcomes in relapsing multiple sclerosis patient subgroups in the ULTIMATE I and II studies. EAN 2022 Presentation EPO 394."},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","unstructured":"Steinman L Hartung H-P Alvarez E et al. Ublituximab efficacy in treatment-naive participants with relapsing multiple sclerosis in the phase 3 ULTIMATE I and II studies. AAN 2023 Poster P6.015.","DOI":"10.1212\/WNL.0000000000203095"},{"key":"e_1_3_4_31_2","unstructured":"Arnold D Steinman L Hartung H-P. Ublituximab reduces thalamic volume loss and new lesion formation in participants of the ULTIMATE I & II phase 3 studies. Ectrims 2023 -0ster # 162."},{"key":"e_1_3_4_32_2","article-title":"Ublituximab significantly reduces radiological disease activity at 12 weeks: post-hoc analysis of participants with highly active disease in the ULTIMATE I & II phase 3 studies","author":"Robertson D","year":"2024","unstructured":"Robertson D, Hartung H-P, Arnold D, et al. Ublituximab significantly reduces radiological disease activity at 12 weeks: post-hoc analysis of participants with highly active disease in the ULTIMATE I & II phase 3 studies. AAN 2024.","journal-title":"AAN"},{"key":"e_1_3_4_33_2","unstructured":"Robertson D Steinman L Fox EJ et al. Improved cognitive processing speed with ublituximab in patients with highly active relapsing multiple sclerosis. CMSS 2022 Poster DMT 19."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1473284"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.038"},{"key":"e_1_3_4_37_2","unstructured":"Cree BAC Fox E Hartung H-P et al. Five years of ublituximab in relapsing multiple sclerosis: results from the open-label extension AAN April 5\u20139 2025."},{"key":"e_1_3_4_38_2","unstructured":"Cree BAC Fox E Hartung H-P et al. Ublituximab 5 years progression five years of ublituximab in relapsing multiple sclerosis: results from the open-label extension of ULTIMATE I and II studies. ECTRIMS September 18\u201320 2024 poster # 324."},{"key":"e_1_3_4_39_2","article-title":"No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS)","volume":"9","author":"Lawrence Steinman L","year":"2025","unstructured":"Lawrence Steinman L, Fox E, Hartung H-P, et al. No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS). AAN, April 5\u20139, 2025.","journal-title":"AAN"},{"key":"e_1_3_4_40_2","article-title":"Real-world ublituximab experience at a single US MS center","author":"Boll C","year":"2025","unstructured":"Boll C, Hoyt T, Pashley L, et al. Real-world ublituximab experience at a single US MS center. Actrims 2025.","journal-title":"Actrims"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1527102"},{"key":"e_1_3_4_42_2","first-page":"329","article-title":"Efficacy and tolerability of ublituximab after transitioning from a different disease-modifying therapy: updates from the ENHANCE study","author":"Foley J","year":"2024","unstructured":"Foley J, Miller T, Wray S, et al. Efficacy and tolerability of ublituximab after transitioning from a different disease-modifying therapy: updates from the ENHANCE study. Ectrim 2024, poster 329.","journal-title":"Ectrim"},{"key":"e_1_3_4_43_2","unstructured":"TG Therapeutics. Safety Update August 2025."},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2023.100167"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103364"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18158163"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200094"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261434868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261434868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261434868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:17:53Z","timestamp":1776665873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261434868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"alternative-id":["10.1177\/17562864261434868"],"URL":"https:\/\/doi.org\/10.1177\/17562864261434868","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17562864261434868"}}